Regeneron (REGN) Q3 Earnings and Revenues Surpass Estimates

Core Insights - Regeneron reported quarterly earnings of $11.83 per share, exceeding the Zacks Consensus Estimate of $9.44 per share, but down from $12.46 per share a year ago, resulting in an earnings surprise of +25.32% [1] - The company achieved revenues of $3.75 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 4.38% and showing a slight increase from $3.72 billion year-over-year [2] - Regeneron has outperformed consensus EPS estimates three times in the last four quarters and has also topped revenue estimates three times during the same period [2] Earnings Outlook - The future performance of Regeneron shares will largely depend on management's commentary during the earnings call and the sustainability of the stock's price movement based on recent earnings and future expectations [3][4] - The current consensus EPS estimate for the upcoming quarter is $9.35 on revenues of $3.67 billion, while for the current fiscal year, the estimate is $40.08 on revenues of $13.95 billion [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Regeneron belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked using tools like the Zacks Rank [5][6]